UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 | Delaware | 1311 | 98-1582153 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code Number) | Identification Number) | (469) 398-2200 (Registrant's telephone number, including area cod ...

Product Development and Market Approval - ONS-5010/LYTENAVA is the first ophthalmic formulation of bevacizumab approved in the EU and UK for wet AMD, with plans to launch in the US in Q2 2025[110]. - The FDA issued a Complete Response Letter for the BLA of ONS-5010/LYTENAVA on August 29, 2023, citing CMC issues and the need for an additional clinical trial[115]. - The NORSE EIGHT trial, involving 400 subjects, did not meet the pre-specified non-inferiority endpoint at week 8, but showed improvement in vision and a favorable safety profile[119]. - The mean improvement in best corrected visual acuity (BCVA) was +4.2 letters for ONS-5010/LYTENAVA and +6.3 letters for ranibizumab at week 8[119]. - The FDA's PDUFA goal date for a decision on the resubmitted BLA is August 27, 2025, with potential for 12 years of regulatory exclusivity if approved[116]. - The company has agreements with the FDA on SPAs for three additional registration clinical trials for ONS-5010/LYTENAVA[121]. Financial Performance and Losses - The company reported a net loss of $46.4 million for the three months ended March 31, 2025, compared to a net loss of $114.3 million for the same period in 2024, reflecting a decrease of $67.9 million[146]. - The company anticipates incurring additional losses until significant sales of ONS-5010/LYTENAVA or other product candidates can be generated[125]. - The company has substantial doubt about its ability to continue as a going concern, as existing cash and cash equivalents are insufficient to fund operations for the next year[127]. - Net loss for the six months ended March 31, 2025 was $28.98 million, a significant improvement compared to a net loss of $125.47 million for the same period in 2024, reflecting a change of $96.49 million[155]. - The company has incurred net losses and negative cash flows from operations, funding its activities with $584.0 million in net proceeds from equity and debt securities[163]. Research and Development Expenses - Research and development expenses decreased by $9.1 million to $4.4 million for the three months ended March 31, 2025, primarily due to a reduction in expenses related to the ONS-5010/LYTENAVA development[147]. - Research and development expenses for the six months ended March 31, 2025 decreased by $4.0 million to $14.1 million compared to $18.0 million for the same period in 2024, primarily due to a $3.3 million decrease in ONS-5010/LYTENAVA development expenses[156]. General and Administrative Expenses - General and administrative expenses increased by $2.6 million to $8.0 million for the three months ended March 31, 2025, driven by prelaunch expenses for ONS-5010/LYTENAVA in Europe[148]. - General and administrative expenses increased by $8.7 million to $19.9 million for the six months ended March 31, 2025, driven by $4.7 million in prelaunch expenses for ONS-5010/LYTENAVA in Europe[157]. Financing and Capital Management - The company has funded operations with $584.0 million in net proceeds from equity and debt securities and $29.0 million from collaboration and licensing agreements as of March 31, 2025[125]. - The company anticipates needing additional financing to fund operations and fully commercialize ONS-5010/LYTENAVA, exploring various strategic opportunities for funding[164]. - The company sold 1,926,742 shares of common stock under the At-the-Market Offering, generating approximately $3.2 million in net proceeds during the six months ended March 31, 2025[166]. - On March 13, 2025, the company issued an unsecured convertible promissory note for $33.1 million to pay off the December 2022 Note[170]. - The company recognized warrant inducement charges associated with warrants exercised, resulting in net proceeds of $15.9 million from the Warrant Inducement Transaction[171]. - The company plans to finance future operations through licensing arrangements, equity issuance, and potential product sales, with risks of dilution and unfavorable terms[178]. Market Overview - The total anti-VEGF retina market in Europe is estimated at approximately $3.6 billion, with around 1.52 million treated patients and 8.3 million total anti-VEGF units[111]. - The US anti-VEGF retina market is estimated at $8.5 billion, with 55% of off-label repackaged bevacizumab injections used as first-line agents[112]. - The global market for anti-VEGF retina is approximately $16 billion[113]. Economic Factors - Macroeconomic factors, including inflation and interest rates, may adversely affect the rollout of LYTENAVA in key markets[122]. Cash Flow and Operating Activities - Net cash used in operating activities for the six months ended March 31, 2025, was $27.6 million, primarily due to a net loss of $29.0 million[180]. - Net cash provided by financing activities during the same period was $20.2 million, driven by proceeds from the issuance of the March 2025 Note and warrant exercises[182]. Warrant and Liability Management - The loss from change in fair value of warrant liability was $42.3 million for the six months ended March 31, 2025, compared to a gain of $49.7 million for the same period in 2024, reflecting a change of $92.0 million[155]. - Syntone agreed to exercise existing warrants for 1,071,429 shares at a reduced price of $2.51, with potential net proceeds of approximately $2.4 million pending regulatory approval[172]. - The conversion price for the March 2025 Note is set at $2.26 per share, subject to adjustments based on market conditions[190].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in its Charter) Delaware 04-2621506 (State or Other Jurisdiction of Incorporation or Organization) Flat A1, 29/F, Block A, TML Tower, 3 Hoi Shing Road, Tsuen Wan, Hong Kong (Address of Principal Executive Of ices) (Zip Code) For the quarterly period ended March 31, 2025 or Registrant's Tel ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM_________ to________ COMMISSION FILE NUMBER 001-4147 Treasure Global Inc (Exact name of registrant as specified in its charter) Delaware 36-4965082 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 (State or o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) | Delaware | 59-2262718 | | --- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Traws Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3627252 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 12 Penns Trail, Newtown, PA 18940 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Registrant's telephone number, including area code: (267) 759-3680 Securities registered pursuant to Section 12(b) of the Act: Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Traws Pharma ...

Financial Performance - Total revenue for the three months ended March 31, 2025, was $9.889 million, compared to $0 in the same period in 2024, representing a significant increase [127]. - The net loss for the three months ended March 31, 2025, was $36.638 million, an improvement of $5.290 million compared to a net loss of $41.928 million in 2024 [127]. - Revenue for the three months ended March 31, 2025, was $9.9 million, primarily from collaboration with Chiesi, including a one-time development cost reimbursement [128]. Research and Development - Research and development expenses for the three months ended March 31, 2025, were $38.041 million, an increase of $5.649 million from $32.392 million in 2024 [127]. - Research and development expenses increased to $38.0 million for the three months ended March 31, 2025, up from $32.4 million in the same period of 2024, reflecting a $5.6 million increase mainly due to costs for seralutinib [129]. - The company has an accumulated deficit of $1.305 billion as of March 31, 2025, reflecting the ongoing investment in research and development [111]. Expenses - General and administrative expenses decreased to $8.658 million in the first quarter of 2025 from $9.567 million in 2024, a reduction of $909,000 [127]. - General and administrative expenses decreased to $8.7 million for the three months ended March 31, 2025, down from $9.6 million in 2024, primarily due to a $1.6 million decrease in stock-based compensation [131]. Cash and Liquidity - As of March 31, 2025, the company had $257.9 million in cash, cash equivalents, and marketable securities, providing a solid financial foundation for ongoing operations [110]. - Cash, cash equivalents, and marketable securities totaled $257.9 million as of March 31, 2025, providing liquidity for ongoing operations [136]. - Net cash used in operating activities for the three months ended March 31, 2025, was $39.7 million, compared to $52.3 million in the same period of 2024 [143]. - Investing activities provided approximately $22.1 million of cash during the three months ended March 31, 2025, primarily from maturities of marketable securities [146]. - Financing activities generated $0.5 million of cash for the three months ended March 31, 2025, mainly from the issuance of common stock [148]. Future Outlook - The company expects to incur significant operating losses for the foreseeable future as it continues the development of seralutinib and seeks regulatory approvals [111]. - Future capital requirements will depend on various factors, including the costs of clinical trials for seralutinib and the ability to generate product revenues [152]. - The company expects to finance its cash needs through equity offerings, debt financings, or other capital sources until it can generate substantial product revenues [113]. - The company expects to finance cash needs through equity offerings, debt financings, or collaborations, but may face challenges in raising additional funds [153]. Clinical Development - The company anticipates activating the first clinical sites for the global registrational Phase 3 SERANATA Study for PH-ILD in the fourth quarter of 2025 [108]. - Under the Chiesi Collaboration Agreement, the total potential transaction value includes a one-time $160 million development cost reimbursement payment [112].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ Commission File Number: 001-34449 PLANET GREEN HOLDINGS CORP. (Exact name of registrant as specified in its charter) (State or other jurisdicti ...